
Biomarker
- Algorithms
- Billing code
- Biomarker
- Cancer of Unknown Primary
- DNA
- End of Treatment
- Hartwig Medical Database
- Hartwig Medical Foundation
- IT
- Lab process
- Learning healthcare system
- Molecular diagnostics
- OncoAct
- Participating hospitals
- Patients' stories
- Personalized treatment
- Quality
- Rare cancers
- Research
- Scientific publications
- Uncategorized
- Whole genome sequencing
- Working in the cloud

Towards a learning healthcare system by broad collaboration
Developing a new drug is expensive and takes a long time. In addition, there is only a slim chance that …

Unraveling of genetic mechanism behind tumor formation may improve targeted treatment for cancer patients
Genetic alterations in the FGFR2 gene occur in various cancer types and represent a promising target for therapies. However, clinical …

Growth Fund invests 325 million euros in Oncode-PACT to accelerate the development of cancer drugs
The National Growth Fund invests 325 million euros in the Oncode-PACT plan to accelerate the preclinical development process of cancer …

SAGE: New algorithm for analysis of tumor DNA reveals mutations previously not found
At Hartwig we “analyse sequenced tumor DNA”. This is something we try to continuously improve. These analyses are shared with …

Nature publication: High resolution DNA-image of metastatic tumor provides new treatment insights
For the first time, Dutch researchers have created a detailed overview of the landscape of DNA-deviations in thousands of metastatic …

We want to extract the maximum amount of information from the patient’s tumor. This DNA test is the The complete DNA test is the best available tool to extract the maximum amount of information from the patient’s tumor. We only need one tissue sample with sufficient tumor cells. We literally analyze the entire genome, including parts of the DNA that show mutations of which we don’t yet know the importance. This test is tumor-independent and future-proof. These are the two most important advantages of WGS.